UH Case Medical Center first surgical site to test regen treatment for chronic stroke

April 26, 2016, University Hospitals Case Medical Center

University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.

"With strokes, focus has been on prevention or treatment within the first few hours," said Jonathan Miller, MD, Director of the Center for Functional and Restorative Neurosurgery at UH Case Medical Center and Assistant Professor of Neurosurgery at Case Western Reserve University School of Medicine, who performs the stem cell surgery as part of the study. "Stroke is the leading cause of adult disability in the U.S., and there really hasn't been much for this patient population."

Ischemic strokes account for approximately 87 percent of all strokes in the US and occur when there is an obstruction in a blood vessel supplying oxygen to the brain. With approximately 800,000 strokes occurring in the United States every year, stroke is the leading cause of acquired disability in the United States. Traditional stroke treatments generally show little or no improvement in patients after the first six months following a stroke.

The ACTIsSIMA "Allogeneic Cell Therapy for Ischemic Stroke to Improve Motor Abilities" trial will examine the effects of genetically modified adult bone-marrow-derived in patients who have experienced an ischemic stroke in the previous six months to five years and still suffer from motor impairments.

Dr. Miller said, "For the hundreds of thousands of people living with the debilitating effects of ischemic stroke, the ACTIsSIMA trial will help determine whether this investigational cell therapy is a safe and effective treatment option."

The Phase 2b clinical trial follows a previous open label Phase 1/2a clinical trial in a similar patient population. The Phase 2b study will further evaluate the safety and efficacy of the treatment in a blinded and controlled setting.

The study will enroll 156 patients with chronic motor deficits after stroke. They are being recruited through 50 assessment sites throughout the United States. Patients will range in age from 18 to 75 years of age. Once enrolled through an assessment site, patients will come to one of 18 surgical sites such as UH Case Medical Center, for the injection of cells. The patient will then be monitored for the duration of the study at the assessment sites. The closest assessment sites to UH are in Toledo and Detroit.

The ACTIsSIMA trial will further evaluate the safety and efficacy of intracranial administration of modified adult bone-marrow-derived stem cells when administered to patients with chronic motor deficit secondary to ischemic stroke.

"UH Case Medical Center has been in the forefront of adult stem cell research," said Dr. Miller. "We are excited to be part of this study to evaluate the potential of this treatment for . Although it will take time, this study and others involving stem cells, may lead to new methods of helping ."

Explore further: Stroke patients show higher recovery in MultiStem therapy

Related Stories

Stroke patients show higher recovery in MultiStem therapy

February 24, 2016
Data presented by the biotech company Athersys indicate that stroke patients treated by an adult stem cell therapy called MultiStem did significantly better than others who received a placebo one year after treatment. The ...

University of Kentucky offers stroke stem cell trial

January 13, 2012
The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult ...

Safety results of intra-arterial stem cell clinical trial for stroke presented

October 11, 2012
Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

Imaging, not time, may determine who is right for stroke clot removal

February 17, 2016
Brain imaging may accurately identify patients likely to benefit from stroke clot removal instead of relying on the time since symptoms began as an indicator of treatment eligibility, according to research presented at the ...

Migraine with aura linked to clot-caused strokes

February 17, 2016
People who have migraines with aura are more likely to have strokes caused by either a blood clot in the heart (cardio-embolic stroke) or a clot within the brain's blood vessels (thrombotic stroke), compared to those that ...

Northwestern Medicine researchers investigate stem cell therapy for stroke

February 11, 2013
Each year, nearly 800,000 Americans suffer a stroke which can result in permanent brain damage, long term disability or death. As a leading cause of adult disability, stroke has an annual burden of more than $62 billion on ...

Recommended for you

New algorithm more accurately predicts life expectancy after heart failure

May 17, 2018
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more ...

New genes found that determine how the heart responds to exercise

May 17, 2018
A new study by researchers at Queen Mary University of London and University College London (UCL) has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.

Novel therapy inhibits complement to preserve neurons and reduce inflammation after stroke

May 16, 2018
A team of investigators at the Medical University of South Carolina (MUSC) has developed a novel therapy for ischemic (clot-caused) stroke and has shown in a preclinical model that it locally inhibits complement at and around ...

Greater burden of atrial fibrillation linked to higher stroke risk

May 16, 2018
Among people with intermittently recurring atrial fibrillation who are not taking anti-blood-clotting medications, those whose hearts were in abnormal rhythms longer were three times more likely to have strokes or other types ...

Stroke prevention drug combo shows promise, study says

May 16, 2018
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research ...

New treatment option for 'wake-up' stroke patients

May 16, 2018
Detail revealed in MRI brain scans can help doctors accurately deduce when a stroke begins, according to new research, allowing treatment for many patients who currently cannot receive it.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.